The long-term safety and efficacy of omalizumab, alongside promising phase 3 trial results that demonstrated the efficacy and ...

For patients with symptomatic chronic spontaneous urticaria after treatment with second-generation H 1-antihistamines, administration of the oral, highly selective Bruton's tyrosine kinase ...

Dr Adam Friedman discusses the clinical impact of CSU updates, highlighting emerging therapies, dietary insights, and patient ...

O'Hollaren, MD, has disclosed that he has served as an advisor or consultant to and has served on the speaker's bureau for GlaxoSmithKline, Merck, Aventis, AstraZeneca, Pfizer, Schering, and IVAX ...